Spectrum Science CEO Jonathan Wilson Appoints Amy Hutnik as President

Hutnik to Lead Spectrum's Expanded Strategic Platform of End-to-End Solutions for Pharma, Biotech, Health Tech and Life Science Clients Under a Single P&L

Spectrum Science, a full-service strategic platform offering integrated engagement, retention, marketing, communications and advisory services for the health and life science industries, today announced the appointment of Amy Hutnik to the role of President. Hutnik currently serves as the company’s Chief Commercial Officer and will continue in that role during the transition. Jonathan Wilson will remain CEO and an Executive Member of the Board with a focus on setting the vision and ensuring a foundation for continued growth.

In her new role, Hutnik will lead Spectrum’s global platform of integrated services including enterprise-wide operations and growth planning across the company’s four strategic pillars: Scientific Communications, Advertising & Consulting, Clinical Trial Experience and Spectrum Science Europe. Presidents of each respective pillar, as well as the leaders of shared services, including strategy, innovation, creative and operational leadership, will report directly to Hutnik.

“I’m delighted to elevate Amy to this new role of President across our greatly expanded organization, and excited to partner with her to facilitate our continued growth,” said Wilson. “The past few years have been remarkable in terms of our evolution from a marketing and communications agency to a full strategic platform purposefully built for maximum integration, across the clinical and commercial landscape. It’s the realization of a vision that my leadership team and I put in motion several years ago. Now, with her diverse background across marketing communications, patient recruitment and consulting, as well as proven operational success, Amy brings the fresh perspective and energy we need to solidify Spectrum’s standing as the partner of choice for innovators in the health and life science industries.”

Over the past several years, Spectrum has grown its capabilities, evolving in lockstep with the rapidly changing needs of the industry. In early 2023, Spectrum entered a strategic partnership with Knox Lane to fuel continued growth. Over the past 6 months, Spectrum completed the strategic acquisitions of CrowdPharm, Hot Iron Health and Continuum Clinical, expanding the company’s offerings in advertising, consulting and clinical trial engagement, respectively.

“In my career across clinical and commercial development, I have been fortunate to be a part of some very smart and strategic teams looking to design solutions for health and life science clients facing a rapidly changing landscape, but none as exciting as Spectrum,” said Hutnik. “There are companies that grow by building from within, and others that expand by adding new and different capabilities to an existing core. In my experience, Spectrum has the unique distinction of evolving through a thoughtful combination of the two – bringing discrete elements together and grounding them on a foundation of scientific and strategic fluency that yields an unparalleled total offering. I am honored and humbled to be stepping into this leadership role, partnering with Jonathan and our leadership team to take Spectrum to new heights in service of greater health for all.”

A 25-year industry veteran, Hutnik has excelled in various executive positions, and is known for building depth in commercialization, communications and growth capabilities at industry-leading companies including Syneos Health and EVERSANA. Since joining Spectrum in August 2023, Hutnik has played a key role in the company’s expansion and evolution into formally established pillars built on a shared science- and strategy-first foundation.

For more such updates, follow us on Google News Martech News

Previous ArticleNext Article